Pfizer, migraine

Pfizer to pay nearly $60M over kickbacks for migraine drug once promoted by Lady Gaga
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT,
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
Pfizer will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs, resulting in the submission of false claims to federal healthcare programs.
Pfizer to pay $60 million to settle claims that Biohaven paid kickbacks to doctors
The alleged violations occurred before Pfizer bought Biohaven and its migraine treatment three years ago for $11.6 billion.
Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.
Pfizer’s Subsidiary Biohaven Settles for Nearly $60M Over Speaker Programs: Complaint included Significant Open Payments Under Reporting
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to improper physician remuneration. This settlement marks a pivotal moment in pharmaceutical compliance,
Pfizer Settles $59.7M Medicare Kickback Case Over Biohaven Practices
Pfizer (NYSE:PFE) has agreed to pay $59.7 million to resolve allegations that Biohaven Pharmaceuticals, acquired by Pfizer in October 2022, defrauded Medicare and other healthcare programs by offering kickbacks to
BioSpace1h
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts
Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...
STAT12d
Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
Is Pfizer Stock a Buy?
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Pfizer going 'all in' on obesity drug development, CEO Bourla says
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
FiercePharma1d
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...
Australian Associated Press3d
Pfizer CEO did not say COVID vaccines are ‘quite dangerous’ in TV interview
Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
Cherokee Phoenix2d
OKC Indian Clinic announces contribution from Pfizer to support Native women’s health
Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...